ly3298176 tirzepatide Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial Tirzepatide 60mg Lyophilized Peptide Vial

The self-reporting part is an important limitation peoples reporting of their weight tends to be imprecise and well need more definitive proof from the Centers for Disease Control and Prevention to be sure, but its some of the earliest evidence that the US may finally be turning a corner on one of the biggest health crises of the modern age

This effect is usually mild and not dangerous for most people

however, human data are limited, with isolated reports on druginduced thyroiditis and thyrotoxicosis

The key point is context

Topline data from the randomized, double-blind, placebo-controlled Phase 3 HOPE-3 (NCT05126758) trial are pending

data from IQVIA